ITI-007

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
TheStreet.com
Thu, 03/9/17 - 11:25 am
FDA
drug approvals
Alkermes
ALKS-5461
CytRx
aldoxorubicin
Dynavax Technologies
HEPLISAV-B
Intra-Cellular Therapies
ITI-007
Novan
SB204
Portola Pharmaceuticals
betrixaban
PTC Therapeutics
ataluren
Rigel Pharmaceuticals
fostamatinib
TG Therapeutics
ublituximab
3 Biotech Stocks With 2016 Phase 3 Data That Could Have Huge Upside Potential
24/7 Wall St
Mon, 01/11/16 - 06:34 pm
biotech
Aerie Pharma
Rhopressa
ITI-007
Intra-Cellular Therapies
These Drugs Could Deliver $5 Billion (or More) in Annual Sales
Motley Fool
Sun, 11/1/15 - 11:12 am
Receptos
Celgene
ozanimod
Novo Nordisk
Intra-Cellular Therapies
ITI-007